Editas Medicine (EDIT) PT Lowered to $37 at Morgan Stanley
Tweet
Share
E-mailGet Alerts EDIT Hot Sheet
Price: $2.62 +3.97%
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Rating Summary:
13 Buy, 12 Hold, 3 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 15 | New: 50
Join SI Premium – FREE
Morgan Stanley analyst Matthew Harrison lowered the price target on Editas Medicine (NASDAQ: EDIT) to $37.00 (from $40.00) while maintaining a Underweight rating.
You May Also Be Interested In
- Macquarie Upgrades Merdeka Gold Resources (EMAS:IJ) to Neutral
- Krung Thai Bank PCL (KTB:TB) PT Raised to THB49 at Macquarie
- Hindustan Unilever Ltd (HUVR:IN) PT Lowered to INR2,750 at Macquarie
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
